ArticlebioRxiv : the preprint server for biology2026
Drug design using unique conformations to preferentially target a specific site on collagen-bound MMP1.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
3 authors.
Funding
Abstract
Precise site-specific drug design remains a challenge in structure-based drug discovery. Most existing approaches screen for ligands to target binding pockets on a protein surface based on static structures obtained from techniques such as X-ray, NMR, cryo-EM, and AlphaFold. However, the structure-function paradigm is, in reality, a structure-dynamics-function relationship that determines a protein's binding and activity. As such, drug screening or design without evaluating binding competition across the protein surface or considering the receptor's dynamic, substrate-dependent conformational states is incomplete. Substrate-specific unique protein conformations are underexplored and offer novel opportunities for selective therapeutic targeting, though systematic workflows for identifying and exploiting such sites remain limited. Previously, we showed that collagen alters matrix metalloprotease-1 (MMP1) dynamics and that R405 is an allosteric residue on the MMP1 surface that exhibits strong dynamic correlations with its active site. Here, we present a substrate-specific allosteric drug-design framework that targets specific sites on a protein, using collagen-bound MMP1 as a model system. We determined the conformational dynamics of free and collagen-bound MMP1 using all-atom molecular dynamics (MD) simulations and categorized conformations into clusters of similar conformations. We then compared and identified unique conformations that occur only in collagen-bound MMP1 to design drugs against them using a machine-learning approach. The top three unique clusters were used to generate approximately 150,000 candidate compounds that were then screened against both the R405-centered region and all detectable binding pockets across the MMP1 surface. We have found several compounds that bind preferentially around R405 by at least 0.3 kcal/mol relative to competing sites across the surface. This strategy establishes a generalizable framework for designing ligands that preferentially target substrate-specific allosteric sites, providing new opportunities for precision therapeutics that modulate proteins in their biologically relevant functional states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.